CEO of ChemoCentryx to Present at GTCbio’s 6th Cytokines and Inflammation (January 28-29, 2008, Orlando, Florida)
Monrovia, CA, January 09, 2008 --(PR.com)-- Thomas Schall, President & CEO of ChemoCentryx will give a presentation entitled “Inhibition of CCR9 as a Therapeutic Approach: Beyond the Small Intestine” at GTCbio’s 6th Cytokines and Inflammation (January 28-29, 2008, Orlando, Florida.)
CCR9 is a chemokine receptor known to play a pivotal role in migration of T-cells to the mucosal surface of the gut. It is well established that CCR9 is critical for T-cell homing to the small intestine. ChemoCentryx has recently found that CCR9 is also critical for development of ulcerative colitis in animal models, indicating a role for this chemokine receptor in cell migration to the large bowel.
One of the earliest investigators in the field of chemokine biology, Dr. Thomas Schall founded ChemoCentryx in 1997 to focus on the discovery and development of chemokine-based therapeutics. Prior to founding ChemoCentryx, Dr. Schall spent several years at a division of Schering Plough, the DNAX Research Institute, where he made fundamental contributions to the understanding of chemokines and their receptors in human in disease. Before that Dr. Schall served for some years as a scientist with Genentech, Inc. During his scientific career, Dr. Schall published over 100 articles in noted peer-reviewed journals.
The conference also features presentations from other leading organizations such as Amgen, AstraZeneca, Biogen Idec, FDA, Genentech, Merck, NIH, Novo Nordisk, Pfizer, Roche, Schering Plough, and many more. The full agenda is available online at www.gtcbio.com.
GTCbio’s 6th Cytokines and Inflammation conference will take place on January 28-29, 2008 at the Orlando Metropolitan Resort in Orlando, Florida and will cover Cytokines Signaling and Regulation, Inflammation and Cancer, Technological Developments in Cytokines Biology, Chemokines, and Targeting of Cytokine Receptors
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/userAgenda.aspx?id=115
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com
###
CCR9 is a chemokine receptor known to play a pivotal role in migration of T-cells to the mucosal surface of the gut. It is well established that CCR9 is critical for T-cell homing to the small intestine. ChemoCentryx has recently found that CCR9 is also critical for development of ulcerative colitis in animal models, indicating a role for this chemokine receptor in cell migration to the large bowel.
One of the earliest investigators in the field of chemokine biology, Dr. Thomas Schall founded ChemoCentryx in 1997 to focus on the discovery and development of chemokine-based therapeutics. Prior to founding ChemoCentryx, Dr. Schall spent several years at a division of Schering Plough, the DNAX Research Institute, where he made fundamental contributions to the understanding of chemokines and their receptors in human in disease. Before that Dr. Schall served for some years as a scientist with Genentech, Inc. During his scientific career, Dr. Schall published over 100 articles in noted peer-reviewed journals.
The conference also features presentations from other leading organizations such as Amgen, AstraZeneca, Biogen Idec, FDA, Genentech, Merck, NIH, Novo Nordisk, Pfizer, Roche, Schering Plough, and many more. The full agenda is available online at www.gtcbio.com.
GTCbio’s 6th Cytokines and Inflammation conference will take place on January 28-29, 2008 at the Orlando Metropolitan Resort in Orlando, Florida and will cover Cytokines Signaling and Regulation, Inflammation and Cancer, Technological Developments in Cytokines Biology, Chemokines, and Targeting of Cytokine Receptors
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/userAgenda.aspx?id=115
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com
###
Contact
GTCbio
Tiffany Chin
626-256-6405
www.gtcbio.com
Tiffany Chin
626-256-6405
www.gtcbio.com
Contact
Categories